<DOC>
	<DOCNO>NCT02737774</DOCNO>
	<brief_summary>This prospective , open , single-center , phase Ⅱ study ass efficacy safety alternate Icotinib chemotherapy advance non-small cell lung cancer EGFR mutation .</brief_summary>
	<brief_title>Alternating Icotinib Chemotherapy Advanced Non-small Cell Lung Cancer With EGFR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Histological cytological confirmation nonsmall cell lung cancer ( NSCLC ) phase ⅢB phase Ⅳ . 2 . Positive EGFR mutation ( 19 exon 21 exon ) 。 1 . Previous usage EGFRTKI antibody EGFR : gefitinib , erlotinib , herceptin , erbitux . 2 . Severe systemic disease control unstable uncompensated respiratory , cardiac , liver , renal disease . 3 . Allergic icotinib 4. metastasis spinal cord , meninges meningeal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Icotinib</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>EGFR</keyword>
</DOC>